Table 2 Prices of several hormonal agents for prostate cancer in Australia (as of January 2016)
Hormonal agent/s | Form and strength | Price ($AUD) | Reference | |
|---|---|---|---|---|
Full price | PBS (maximum number of repeats for PBS price) | |||
Advanced or high-risk hormone naïve prostate cancer (clinical tumor stages T3–T4, PSA > 20 ng/mL) | ||||
Goserelin acetate | 3.6 mg implant | $323.50 | $38.30 (5) | [114] |
10.8 g implant | $1101.16 | $38.30 (1) | [114] | |
Triptorelin acetate | 3.75 mg injection | $413.75 | $38.30 (5) | [115] |
22.5 mg injection | $2123.34 | $38.30 (0) | [115] | |
Goserelin acetate and Bicalutamide | 3.6 mg implant and 50 mg tablet (28 tablets), respectively | $472.81 | $38.30 (5) | [116] |
10.8 mg implant and 50 mg tablet (28 tablets), respectively | $1240.02 | $38.30 (0) | [116] | |
Leuprorelin (or leuprolide) acetate | 30 mg injection | $1442.09 | $38.30 (1) | [117] |
Degarelix | 80 mg injection | $413.75 | $38.30 (5) | [118] |
120 mg injection | $432.92 | $38.30 (0) | [118] | |
Bicalutamide | 50 mg tablet (28 tablets) | $98.40 | $38.30 (5) | [119] |
Flutamide | 250 mg tablets (100 tablets) | $169.70 | $38.30 (5) | [120] |
Nilutamide | 150 mg tablet (30 tablets) | $223.68 | $38.30 (5) | [121] |
Metastatic castration-resistant prostate cancer (mCRPC) (histologically confirmed prostate cancer, N1/M1, more than two [or three in other studies] consecutive rises in PSA levels over 25 % above nadir value following surgical or chemical ADT for at least 1 week) | ||||
Abiraterone acetate | 250 mg tablet (120 tablets) | $3600.41 | $38.30 (2) | [122] |
Enzalutamide | 40 mg capsule (112 capsules) | $3700.17 | $38.30 (2) | [123] |